Document is current
Any future updates will be listed below
-
Authors
Paul, F. https://orcid.org/0000-0002-6378-0070
Zappacosta, S.
Narduzzi, S. https://orcid.org/0000-0003-2539-9583
Khellaf, M.
Unsworth, M. https://orcid.org/0000-0003-4683-2833
Trenholm, E. https://orcid.org/0009-0003-1737-3698
-
Funding
Funding for this research was provided by:
UCB
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 23 January 2025
Revised: 20 June 2025
Accepted: 25 June 2025
First Online: 22 July 2025
Declarations
:
: F Paul has received research support, speaker honoraria and travel reimbursement from Bayer, Biogen Idec, Merck Serono, Novartis, Sanofi Genzyme, UCB and Teva; is supported by the German Research Council (DFG Exc 257) and the German Competence Network of Multiple Sclerosis; has received travel reimbursement from the Guthy-Jackson Charitable Foundation; and serves on the steering committee of the OCTiMS study sponsored by Novartis. S Zappacosta is an employee of UCB. S Narduzzi is an employee and shareholder of UCB. M Khellaf was an employee of UCB at the time the study was conducted. M Unsworth and E Trenholm are employees of Adelphi Real World (Bollington, United Kingdom) and have no conflicts of interest to declare. M Levy has received consulting income for work with Alexion, Genentech, Horizon, Mitsubishi, Sanofi, and UCB.Ethical considerationsThe DSP complies with all relevant guidelines and legal obligations in the countries where the survey was conducted, and in accordance with the Declaration of Helsinki (1964). Data were collected according to European Pharmaceutical Marketing Research Association guidelines and thus did not require ethics committee approvals. The survey materials were submitted to the PEARL Institutional Review Board (REF: #22-ADRW-138) and following review were deemed to be exempt. The survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 and Health Information Technology for Economic and Clinical Health Act legislation. Data were collected in such a way that patients and physicians could not be identified directly. All data were anonymised and aggregated prior to receipt and analysis.
: Using a checkbox, patients provided informed consent to take part in the survey and for use of their anonymised and aggregated data for research and publication in scientific journals.
